HUP0500457A3 - Polyalkylene polymer compounds, compositions containing the same and uses thereof - Google Patents

Polyalkylene polymer compounds, compositions containing the same and uses thereof

Info

Publication number
HUP0500457A3
HUP0500457A3 HU0500457A HUP0500457A HUP0500457A3 HU P0500457 A3 HUP0500457 A3 HU P0500457A3 HU 0500457 A HU0500457 A HU 0500457A HU P0500457 A HUP0500457 A HU P0500457A HU P0500457 A3 HUP0500457 A3 HU P0500457A3
Authority
HU
Hungary
Prior art keywords
same
compositions containing
polymer compounds
polyalkylene polymer
polyalkylene
Prior art date
Application number
HU0500457A
Other languages
English (en)
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of HUP0500457A2 publication Critical patent/HUP0500457A2/hu
Publication of HUP0500457A3 publication Critical patent/HUP0500457A3/hu
Publication of HU230473B1 publication Critical patent/HU230473B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
HU0500457A 2002-01-18 2003-01-17 Polialkilén polimervegyületek és azok alkalmazása HU230473B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34991702P 2002-01-18 2002-01-18
US60/349,917 2002-01-18
PCT/US2003/001559 WO2003061577A2 (en) 2002-01-18 2003-01-17 Polyalkylene glycol with moiety for conjugating biologically active compound

Publications (3)

Publication Number Publication Date
HUP0500457A2 HUP0500457A2 (hu) 2005-08-29
HUP0500457A3 true HUP0500457A3 (en) 2012-09-28
HU230473B1 HU230473B1 (hu) 2016-07-28

Family

ID=27613339

Family Applications (4)

Application Number Title Priority Date Filing Date
HU0500457A HU230473B1 (hu) 2002-01-18 2003-01-17 Polialkilén polimervegyületek és azok alkalmazása
HUE03731987A HUE028163T2 (hu) 2002-01-18 2003-01-17 Polialkilén polimervegyületek és felhasználásuk
HUE15203017A HUE047557T2 (hu) 2002-01-18 2003-01-17 Polialkilén polimervegyületek és felhasználásuk
HUS1600035C HUS1600035I1 (hu) 2002-01-18 2016-08-18 Polialkilén polimervegyületek és felhasználásuk

Family Applications After (3)

Application Number Title Priority Date Filing Date
HUE03731987A HUE028163T2 (hu) 2002-01-18 2003-01-17 Polialkilén polimervegyületek és felhasználásuk
HUE15203017A HUE047557T2 (hu) 2002-01-18 2003-01-17 Polialkilén polimervegyületek és felhasználásuk
HUS1600035C HUS1600035I1 (hu) 2002-01-18 2016-08-18 Polialkilén polimervegyületek és felhasználásuk

Country Status (35)

Country Link
US (2) US8017733B2 (hu)
EP (3) EP1476181B1 (hu)
JP (5) JP2005526151A (hu)
KR (1) KR100964411B1 (hu)
CN (2) CN101700401B (hu)
AU (1) AU2003210564B2 (hu)
BE (1) BE2016C040I2 (hu)
BG (1) BG66525B1 (hu)
BR (1) BRPI0306993B8 (hu)
CA (4) CA2473526C (hu)
CY (2) CY2016027I2 (hu)
CZ (1) CZ2004877A3 (hu)
DK (2) DK3025726T3 (hu)
EA (2) EA011829B1 (hu)
EE (1) EE05509B1 (hu)
ES (2) ES2566797T3 (hu)
GE (2) GEP20074024B (hu)
HK (3) HK1072721A1 (hu)
HU (4) HU230473B1 (hu)
IL (1) IL163006A (hu)
IS (1) IS2989B (hu)
LU (1) LU93162I2 (hu)
ME (2) ME00239B (hu)
MX (1) MXPA04006855A (hu)
NL (1) NL300826I2 (hu)
NO (3) NO339857B1 (hu)
NZ (1) NZ534708A (hu)
PL (2) PL213322B1 (hu)
PT (1) PT3025726T (hu)
RS (1) RS55578B1 (hu)
SI (2) SI3025726T1 (hu)
SK (1) SK3102004A3 (hu)
UA (1) UA82184C2 (hu)
WO (1) WO2003061577A2 (hu)
ZA (1) ZA200406555B (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150246097A9 (en) * 2002-01-18 2015-09-03 Biogen Idec Ma Inc. Polyalkylene Polymer Compounds and Uses Thereof
PL213322B1 (pl) * 2002-01-18 2013-02-28 Biogen Idec Inc Kompozycja farmaceutyczna zawierajaca polimer glikolu polialkilenowego skoniugowany z biologicznie aktywnym zwiazkiem lub jego prekursorem oraz jej zastosowania
RS20050202A (en) 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1667708B9 (en) * 2002-12-26 2012-10-31 Mountain View Pharmaceuticals, Inc. POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
EA013535B1 (ru) * 2002-12-26 2010-06-30 Маунтин Вью Фамэсьютикэлс, Инк. Полимерный конъюгат биоактивного компонента (варианты), способ его получения и использования, фармацевтические продукты на его основе
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
JP5229768B2 (ja) 2003-06-26 2013-07-03 シヴィダ・ユーエス・インコーポレイテッド Ｉｎ−Ｓｉｔｕゲル化薬物輸送システム
CA2530113C (en) 2003-06-26 2013-08-13 Control Delivery Systems, Inc. Bioerodible sustained release drug delivery systems
US20090312344A1 (en) * 2004-05-31 2009-12-17 Mohammad Salman Arylpiperazine derivatives as adrenergic receptor antagonists
ES2357089T5 (es) 2004-12-21 2014-02-24 Nektar Therapeutics Reactivos de tiol polimérico estabilizados
WO2006130553A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
KR20080031053A (ko) * 2005-07-08 2008-04-07 엘란 파마슈티칼스, 인크. 치료, 농업 및 식품 첨가제 화합물의 중합체 컨쥬게이트의제조 방법
AU2007253717A1 (en) * 2006-05-22 2007-11-29 Elan Pharmaceuticals, Inc. Preparation of polymer conjugates of therapeutic, agricultural and food additive compounds
US20100222546A1 (en) * 2006-11-28 2010-09-02 David Crich Methods for the preparation of functionalized peptides, proteins and carbohydrates and their conjugates
EP2175878A4 (en) * 2007-07-11 2014-12-03 Belrose Pharma Inc POLYMER DRUG DISPENSING SYSTEM WITH A MULTIPLE SUBSTITUTED AROMATIC PART
WO2009009716A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery systems containing an aromatic allylic acid
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
WO2009149377A1 (en) * 2008-06-05 2009-12-10 Zymogenetics, Llc Use of pegylated type iii interferons for the treatment of hepatitis c
CN102131844B (zh) * 2008-07-31 2016-03-02 药华医药股份有限公司 肽-聚合物缀合物
GB0823309D0 (en) * 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
EP2439736A1 (en) 2009-06-02 2012-04-11 Panasonic Corporation Down-mixing device, encoder, and method therefor
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
US20130225789A1 (en) * 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
KR101475630B1 (ko) * 2013-05-31 2014-12-22 동국대학교 산학협력단 포도근 추출물 또는 이의 분획물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 조성물
US11759500B2 (en) * 2014-07-24 2023-09-19 Abion Inc. PEGylated interferon-beta variant
ES2824028T3 (es) * 2014-08-19 2021-05-11 Biogen Ma Inc Método de PEGilación
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
EP3215193B1 (en) 2014-11-06 2023-10-04 PharmaEssentia Corporation Dosage regimen for pegylated interferon
EP3421442B1 (en) * 2017-06-28 2020-08-05 Construction Research & Technology GmbH Dispersant for inorganic particles
US11472894B2 (en) 2018-07-23 2022-10-18 Carnegie Mellon University Enzyme-assisted ATRP procedures
CN109232898A (zh) * 2018-08-02 2019-01-18 张玲 一种具有抗凝血功能的聚酰亚胺新材料的制备方法
CN111534458B (zh) * 2020-04-13 2022-01-14 浙江工业大学 无色杆菌tbc-1及其在降解1,3,6,8-四溴咔唑中的应用
CN113716982B (zh) * 2021-08-24 2022-05-06 重庆云瑞肥业有限公司 一种食品垃圾回收用发酵制肥装置

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
AU3423293A (en) * 1991-12-19 1993-07-19 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
CA2206852A1 (en) * 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
WO1997014740A1 (en) * 1995-10-19 1997-04-24 Receptagen Corporation Discrete-length polyethylene glycols
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
ATE200030T1 (de) 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc Pegylationsverfahren
WO1998039487A1 (en) 1997-03-05 1998-09-11 Ribogene, Inc. Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US7642323B2 (en) * 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) * 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
CA2312975C (en) * 1997-12-17 2012-08-21 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
EP1061954B1 (en) * 1998-03-12 2004-06-09 Nektar Therapeutics Al, Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
IL139286A (en) * 1998-04-28 2005-12-18 Applied Research Systems Polyol-ifn-beta conjugates, their preparation and use
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
EE04967B1 (et) * 1998-10-16 2008-02-15 Biogen, Incorporated Glkoslitud interferoon-beeta, selle kasutamineja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
JP2003503367A (ja) * 1999-06-11 2003-01-28 シアウォーター・コーポレイション キトサンとポリ（エチレングリコール）または関連ポリマーから得られるヒドロゲル
IL147581A0 (en) 1999-08-27 2002-08-14 Maxygen Aps New interferon beta-like molecules
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
DK1259562T3 (da) 1999-12-22 2006-04-18 Nektar Therapeutics Al Corp Sterisk hindrede derivater af vandoplöselige polymerer
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP1324779B1 (en) * 2000-09-29 2011-07-20 Schering Corporation Pegylated interleukin-10
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
EE05537B1 (et) * 2001-02-01 2012-04-16 Biogen, Inc. Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks
EP1366075B1 (en) 2001-02-27 2009-05-27 Maxygen Aps New interferon beta-like molecules
US7009033B2 (en) * 2001-07-02 2006-03-07 Polymer Source Inc. Heterofunctional polyethylene glycol and polyethylene oxide, process for their manufacture
DK2939696T3 (en) * 2001-10-18 2016-05-23 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
AU2002356990A1 (en) * 2001-11-20 2003-06-10 Pharmacia Corporation Chemically-modified human growth hormone conjugates
KR100488351B1 (ko) * 2001-12-11 2005-05-11 선바이오(주) 신규한 폴리에틸렌글리콜-프로피온알데히드 유도체
US7041855B2 (en) * 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
EP1507755A4 (en) * 2001-12-11 2006-05-17 Sun Bio Inc NOVEL MONOFUNCTIONAL POLYETHYLENE GLYCOL ALDEHYDES
US6956135B2 (en) * 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
PL213322B1 (pl) * 2002-01-18 2013-02-28 Biogen Idec Inc Kompozycja farmaceutyczna zawierajaca polimer glikolu polialkilenowego skoniugowany z biologicznie aktywnym zwiazkiem lub jego prekursorem oraz jej zastosowania
RS20050202A (en) 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
EP1667708B9 (en) * 2002-12-26 2012-10-31 Mountain View Pharmaceuticals, Inc. POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy

Also Published As

Publication number Publication date
CN101700401B (zh) 2013-08-14
EE05509B1 (et) 2012-02-15
LU93162I2 (fr) 2016-10-03
DK3025726T3 (da) 2019-12-09
EP3025726A1 (en) 2016-06-01
EP3025726B1 (en) 2019-11-20
HUS1600035I1 (hu) 2016-10-28
PL397261A1 (pl) 2012-03-26
PL372728A1 (en) 2005-08-08
EP3669887A1 (en) 2020-06-24
CY1122841T1 (el) 2021-10-29
NO339857B1 (no) 2017-02-06
GEP20074024B (en) 2007-01-10
HUE047557T2 (hu) 2020-04-28
SI3025726T1 (sl) 2020-03-31
US20120014916A1 (en) 2012-01-19
NO2017013I2 (no) 2018-08-20
HU230473B1 (hu) 2016-07-28
IS7353A (is) 2004-07-15
IS2989B (is) 2017-11-15
CA2473526A1 (en) 2003-07-31
EA011829B1 (ru) 2009-06-30
CY2016027I1 (el) 2017-06-28
IL163006A (en) 2011-01-31
NL300826I2 (hu) 2017-03-16
US20050107277A1 (en) 2005-05-19
BE2016C040I2 (hu) 2022-05-17
JP2005526151A (ja) 2005-09-02
HK1072721A1 (zh) 2005-09-09
BRPI0306993B8 (pt) 2021-05-25
WO2003061577A3 (en) 2003-10-02
DK1476181T3 (en) 2016-05-23
JP6030717B2 (ja) 2016-11-24
ES2774801T3 (es) 2020-07-22
EE200400105A (et) 2004-12-15
RS63504A (en) 2007-02-05
CN1630530A (zh) 2005-06-22
NO344612B1 (no) 2020-02-10
EP1476181B1 (en) 2016-03-23
JP2012255156A (ja) 2012-12-27
HUP0500457A2 (hu) 2005-08-29
NO2017013I1 (no) 2017-04-10
CZ2004877A3 (cs) 2004-12-15
MEP35608A (en) 2011-02-10
KR20040081463A (ko) 2004-09-21
CA2753899A1 (en) 2003-07-31
EA009783B1 (ru) 2008-04-28
JP2009235409A (ja) 2009-10-15
EA200400962A1 (ru) 2005-06-30
JP2016014022A (ja) 2016-01-28
ES2566797T3 (es) 2016-04-15
EP1476181A2 (en) 2004-11-17
CA2952488C (en) 2019-05-07
AU2003210564B2 (en) 2008-10-23
EP1476181A4 (en) 2008-11-19
CA2840490A1 (en) 2003-07-31
CA2753899C (en) 2014-03-25
HUE028163T2 (hu) 2016-11-28
JP5275125B2 (ja) 2013-08-28
RS55578B1 (sr) 2017-06-30
SI1476181T1 (sl) 2016-10-28
BRPI0306993B1 (pt) 2020-03-10
ME00239B (me) 2011-05-10
EA200701386A1 (ru) 2007-10-26
NZ534708A (en) 2007-05-31
WO2003061577A2 (en) 2003-07-31
CA2952488A1 (en) 2003-07-31
HK1143553A1 (en) 2011-01-07
BR0306993A (pt) 2005-09-06
NO20151082A1 (no) 2015-08-26
UA82184C2 (uk) 2008-03-25
US8017733B2 (en) 2011-09-13
MXPA04006855A (es) 2005-04-19
CN101700401A (zh) 2010-05-05
KR100964411B1 (ko) 2010-06-15
GEP20064024B (en) 2007-01-10
ZA200406555B (en) 2005-11-30
CY2016027I2 (el) 2017-06-28
US8524660B2 (en) 2013-09-03
JP2013136756A (ja) 2013-07-11
SK3102004A3 (sk) 2005-01-03
CA2840490C (en) 2017-02-28
BG108839A (bg) 2005-04-30
CA2473526C (en) 2013-10-22
NO20043422L (no) 2004-10-11
WO2003061577A8 (en) 2008-11-20
BG66525B1 (bg) 2016-04-28
HK1224185A1 (zh) 2017-08-18
PL213322B1 (pl) 2013-02-28
PT3025726T (pt) 2020-01-09

Similar Documents

Publication Publication Date Title
HUP0500457A3 (en) Polyalkylene polymer compounds, compositions containing the same and uses thereof
GB0307891D0 (en) Chemical compounds,compositions and uses
GB0323845D0 (en) Chemical compounds,compositions and uses
AU2003227480A1 (en) Modified polymers and compositions containing the same
HK1080497A1 (en) Carbohydrate-modified polymers, compositions and uses related thereto
ZA200501431B (en) 5-Aryltetrazole compounds, compositions thereof, and uses therefor.
EP1542699A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
AU2003262747A8 (en) Compounds, compositions, and methods
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
EP1617807A4 (en) SUBSTITUTED 1,4-DIAZEPINE AND ITS USES
AU2003270015A8 (en) Compounds, compositions, and methods
AU2003228205A8 (en) Porous polymers: compositions and uses thereof
EP1556056A4 (en) X-Nitro Compounds, Pharmaceutical Compositions And Their Uses
IL158267A0 (en) Polymeric composition
ZA200306629B (en) Polymer modified gypsum composition.
AU2003267169A8 (en) Compounds, compositions and methods
GB2398790B (en) Polymer compositions
GB0207013D0 (en) Polymer composition
GB0205277D0 (en) Azetidinium-functionalised polymer and compositions containing the same
GB0203357D0 (en) Compounds,compositions and uses
EG23194A (en) Polymeric composition.
ZA200409130B (en) Compounds, compositions, and methods.
GB0128005D0 (en) Polymer composition
EG23066A (en) Polymeric composition

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: BIOGEN MA INC., US

Free format text: FORMER OWNER(S): BIOGEN IDEC MA INC., US